MacDermid E, Hooton G, MacDonald M, McKay G, Grose D, Mohammed N, Porteous C
Department of Surgery, Royal Alexandra Hospital, Paisley, UK.
Colorectal Dis. 2009 Mar;11(3):291-5. doi: 10.1111/j.1463-1318.2008.01580.x. Epub 2008 May 9.
There is little information on the impact of the colorectal multi-disciplinary team (MDT) in the United Kingdom. Our single operator presented his patients before and after the inception of an MDT meeting in June 2002. The aim of this study was to assess the effect of this on his patients' survival, and trends in the use of adjuvant chemotherapy.
Data were collected on all patients (n = 310) undergoing colectomy for colorectal cancer by one surgeon. Excluding patients with Dukes A stage, the pre-MDT cohort from January 1997 to May 2002 was 176 and the post-MDT cohort from June 2002 to December 2005 was 134. Three-year survival rates were calculated using Kaplan-Meier life table analysis. Prognostic factors were analysed using Cox-proportional hazard regression, and chemotherapy data analysed using the chi-squared test. Independent prognostic indicators of chemotherapy prescription were examined using binary logistic testing.
MDT status was shown to be an independent predictor of survival on hazard regression analysis (P = 0.044). A significantly greater number of patients were prescribed adjuvant chemotherapy in the post-MDT cohort (P = 0.0002). MDT status was shown to be a significant prognostic indicator of chemotherapy prescription (P < 0.0001). Three-year survival for Dukes C patients was 58% in the pre-MDT group, and 66% in the post-MDT group (P = 0.023).
There was a significant increase in patients undergoing adjuvant postoperative chemotherapy after the inception of the MDT. This was associated with a significant survival benefit in patients with Dukes C disease. The data suggest that the MDT process has resulted in an increase in the prescription of adjuvant chemotherapy, with 3-year survival being greater after its inception.
关于英国结直肠癌多学科团队(MDT)的影响,相关信息较少。我们的单名手术医生在2002年6月MDT会议开始前后分别展示了他的患者情况。本研究的目的是评估这对其患者生存的影响以及辅助化疗使用趋势。
收集了由一名外科医生进行结直肠癌结肠切除术的所有患者(n = 310)的数据。排除Dukes A期患者后,1997年1月至2002年5月的MDT前队列有176例,2002年6月至2005年12月的MDT后队列有134例。使用Kaplan-Meier生存表分析计算三年生存率。使用Cox比例风险回归分析预后因素,使用卡方检验分析化疗数据。使用二元逻辑检验检查化疗处方的独立预后指标。
在风险回归分析中,MDT状态被证明是生存的独立预测因素(P = 0.044)。MDT后队列中接受辅助化疗的患者数量显著更多(P = 0.0002)。MDT状态被证明是化疗处方的显著预后指标(P < 0.0001)。Dukes C期患者在MDT前组的三年生存率为58%,在MDT后组为66%(P = 0.023)。
MDT开始后,接受术后辅助化疗的患者显著增加。这与Dukes C期疾病患者的显著生存获益相关。数据表明MDT流程导致辅助化疗处方增加,其开始后三年生存率更高。